QuantumCell commits $2.2bn on AlzeCure’s Alzheimer’s platform - Pharmaceutical Technology

The lead product on AlzeCure’s platform has already demonstrated positive Phase I results. The lead product on AlzeCure’s platform has already demonstrated positive Phase I results. NeuroRestore develops small-molecule drugs designed to improve cognitive functions, like learning and memory. Credit: rangizzz/Shutterstock.com. Less than a year after emerging from stealth, Danish-based QuantumCell has signed a multi-billion-dollar deal to equip its pipeline with Alzheimer’s drug technology. The biotech has entered into a licensing and collaboration agreement with Swedish company AlzeCure Pharma for rights to the latter’s Alzheimer’s platform NeuroRestore, including the leading drug candidate ACD856. QuantumCell is paying only $12m upfront, but…

Source: Pharmaceutical Technology